



Express Mail No. EV449563042US
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tomas R. Szabo et al.
Application No. : 10/020,867
Filed : December 14, 2001
For : COBALT-PORPHYRIN COMPLEXES AND USE THEREOF AS
AN ANTI-OBESITY AGENT

Examiner : Peter G. O'Sullivan
Art Unit : 1621
Docket No. : 660088.415
Date : November 8, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Commissioner for Patents:

In response to the Office Action mailed May 6, 2004, please extend the period of time for response three months, to expire on November 8, 2004 (November 6, 2004 being a Saturday and November 7, 2004 being a Sunday). Enclosed are a Petition for an Extension of Time and the requisite fee. Please amend the application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.


Remarks/Arguments begin on page 5 of this paper.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A cobalt-porphyrin complex having the structure:



or a salt thereof, wherein:

R_1 and R_2 are both $-(CH_2)_nC(=O)OCH(CH_3)_2$; ~~the same or different and independently $-(CH_2)_n-A-R_5$, wherein A is $-C(=O)O$, $-OC(=O)$, $-C(=O)N(R)$, $-N(R)C(=O)$, $-C(=O)$, $-N(R)$, $-O$ or $-S$, and R is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl, and n is 2 or 3;~~

R_3 and R_4 are both ~~the same or different and independently $-CH=CH_2$ or $-CH_2CH_3$; and~~

R_5 is, ~~at each occurrence, the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and~~


L_1 and L_2 are both glycinate; ~~optional ligands;~~

~~and with the proviso that the cobalt-porphyrin complex of structure (I) has no more than 5% of the redox activity of cobalt mesoporphyrin.~~

2-30. (Cancelled)

~~2~~
~~31.~~ (Original) A composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

~~3~~
~~32.~~ (Currently Amended) A method for treating obesity, comprising administering an effective amount of a composition comprising a cobalt-porphyrin complex and a pharmaceutically acceptable carrier, wherein the cobalt-porphyrin complex has the structure:



or a salt thereof, wherein:

R_1 and R_2 are both $-(CH_2)_2C(=O)OCH(CH_3)_2$; ~~the same or different and independently $-(CH_2)_n-A-R_5$, wherein A is $-C(=O)O-$, $-OC(=O)-$, $-C(=O)N(R)-$, $-N(R)C(=O)-$, $-C(=O)-$, $-O-$ or $-S-$, and R is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl, and n is 2 or 3;~~

R_3 and R_4 are both ~~the same or different and independently $-CH=CH_2$ or $-CH_2CH_3$; and~~

R_5 ~~is, at each occurrence, the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and~~

L_1 and L_2 are both glycinate; ~~optional ligands;~~

~~and with the proviso that the cobalt-porphyrin complex of structure (I) has no more than 50% of the redox activity of cobalt mesoporphyrin.~~

Application No. 10/020,867
Reply to Office Action mailed May 6, 2004

33-62. (Cancelled)